It was a nice announcement. It boosts the backlog by 36% and represents about 27% of a year's sale (though the contracts are for 15 months). It was also nice that it won a new contract in the US, even in the face of tariff fears. The stock had been beaten up pretty badly. It now trades at 4X earnings with a tiny dividend. There is still lots of risk here, but the balance sheet is strong and visibility on growth has improved with this news. We would see it as 'buyable' but more of an accumulate as part of an overall small cap allocation, rather than all at once.
5i Research Answer: